SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from clinical trials involving its vascular disrupting agent (VDA) product candidates, fosbretabulin (ZYBRESTAT™) and OXi4503, will be presented in two posters at the upcoming 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, June 4-8, 2010. In addition, two additional posters describing fosbretabulin and OXi4503 trial designs will be presented in the newly-created “Trials in Progress” poster session. OXiGENE will release a summary of results immediately after they are presented.
